Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Myriad Genetics, Inc. - Common Stock
(NQ:
MYGN
)
13.74
+0.09 (+0.66%)
Streaming Delayed Price
Updated: 1:00 PM EST, Dec 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
348,777
Open
13.60
Bid (Size)
13.23 (2)
Ask (Size)
14.27 (1)
Prev. Close
13.65
Today's Range
13.32 - 13.77
52wk Range
12.87 - 29.30
Shares Outstanding
90,900,000
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics
December 19, 2024
Study Demonstrates RiskScore as a More Accurate Predictor of Breast Cancer Risk, Doubling Accuracy Compared to the Tyrer-Cuzick Model
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing
December 10, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Performance
YTD
-27.68%
-27.68%
1 Month
-12.54%
-12.54%
3 Month
-48.25%
-48.25%
6 Month
-44.28%
-44.28%
1 Year
-32.55%
-32.55%
More News
Read More
Myriad Genetics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
December 09, 2024
Via
Benzinga
Where Myriad Genetics Stands With Analysts
November 18, 2024
Via
Benzinga
Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member
December 10, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics’ Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines
December 10, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium
December 09, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
This AMD Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
December 09, 2024
Via
Benzinga
NCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics' Prolaris® Test as an 'Advanced Tool' Recommended for Prognostic Assessment
December 09, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2
November 20, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy
November 19, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
MYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the Firm
November 14, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch
November 13, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance
November 07, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
MYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the Firm
November 07, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing
November 04, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Crude Oil Moves Higher; Apple Shares Slide After Q4 Results
November 01, 2024
Via
Benzinga
Exposures
Fossil Fuels
12 Health Care Stocks Moving In Friday's Intraday Session
November 01, 2024
Via
Benzinga
Nasdaq Surges Over 200 Points; Amazon Shares Jump After Strong Results
November 01, 2024
Via
Benzinga
Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024
October 30, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics and jscreen™ Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access
October 16, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration
October 15, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer
October 08, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics and Ultima Genomics to Explore the UG 100™ Sequencing Platform to Advance Clinical Test Offerings in Oncology and Reproductive Genomics
October 03, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Myriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
October 01, 2024
From
Myriad Genetics, Inc.
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.